The Experts below are selected from a list of 4830 Experts worldwide ranked by ideXlab platform
Mehmet Haberal - One of the best experts on this subject based on the ideXlab platform.
-
Panel Reactive antibodies in predicting hepatitis C virus treatment outcome in kidney transplant candidates.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2015Co-Authors: Serkan Ocal, Özgür Harmancı, Murat Korkmaz, Fatih Ensaroğlu, Turan Colak, Haldun Selçuk, Gokhan Moray, Mehmet HaberalAbstract:OBJECTIVES: Chronic hepatitis C virus infection compromises hemodialysis patients and increases liver-related mortality. Interferon treatment is associated with improved sustained virological response rates and increased risk of graft loss after kidney transplant. This may be related to the development of antihuman leukocyte antigen antibodies, which may be a surrogate marker of potent immune response. We evaluated Panel Reactive Antibody 1 and 2 levels for prediction of sustained viral response in patients with kidney transplant. MATERIALS AND METHODS: In this retrospective cohort study, we reviewed data from hepatitis C virusinfected hemodialysis patients who received interferon treatment before kidney transplant. Panel Reactive Antibody > 20% was considered positive. Sustained viral response rates for interferon treatment were obtained and compared with Panel Reactive Antibody 1 and 2 values. RESULTS: There were 40 patients (16 female and 24 male patients; mean age, 41.5 y; range, 18-65 y). Sustained viral response rate was 18/40 (45%). Panel Reactive Antibody 1 was negative in 31 patients and positive in 9 patients. Sustained viral response ratio was not correlated with Panel Reactive Antibody 1 positivity. Panel Reactive Antibody 2 was negative in 31 patients (sustained viral response: present, 11 patients; absent, 20 patients) and positive in 9 patients (sustained viral response: present, 7 patients; absent, 2 patients). Sustained viral response ratio was significantly correlated with Panel Reactive Antibody 2 positivity. CONCLUSIONS: We showed a correlation between Panel Reactive Antibody 2 positivity and sustained viral response rates that may be a predictive tool for hepatitis C virus treatment response. In patients with other complications that compromise hepatitis C virus treatment, Panel Reactive Antibody 2 may be a surrogate marker for sustained viral response prediction. The induction of cellular immunity may cause clearance of hepatitis C virus infection and formation of high Panel Reactive Antibody 2 levels.
-
Angiotensin-converting enzyme genotype is a predictive factor in the peak Panel-Reactive Antibody response.
Transplantation proceedings, 2004Co-Authors: Ali Akcay, F N Ozdemir, Siren Sezer, Z Arat, Fatma Belgin Atac, Hasibe Verdi, Mehmet HaberalAbstract:The presence of a high Panel-Reactive Antibody (PRA) level represents an independent risk factor for early graft failure and chronic allograft dysfunction. It has also been reported that patients with the ACE-DD and AGT-AA genotypes display poorer chronic allograft function. We investigated the effects of gene polymorphisms of the renin angiotensin system (RAS) on anti-HLA Antibody production among renal transplant candidates. Genotyping was performed on 133 dialysis patients for the ACE (I/D) and AGT (M235T) as well as the type 1 (A1166C) and type 2 (A1223G) angiotensin II receptor genes. Patients with a peak PRA ≥ 30% were considered to be positive for anti-HLA Antibody (40.6% of 133 patients). Genetic polymorphisms of the RAS were not associated with anti-HLA Antibody production at this PRA level. Another analysis comparing the 29 patients with a peak PRA ≥50% with the 104 patients with a peak PRA
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish renal transplant candidates
Transplant Immunology, 2004Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, E Kulah, Ali Akcay, S Gulmus, Mehmet HaberalAbstract:Abstract Pre- and post-renal transplantation Panel Reactive Antibody (PRA) screening is associated with increased incidence of hyperacute or acute graft rejection and graft loss. This study was designed to find any relationship PRA sensitization and associated human leukocyte antigen (HLA)-specific antibodies in Turkish renal transplant candidates. We included 340 patients who were in the renal transplantation waiting list in the study. We determined PRA sensitization ratio and the associated anti-HLA IgG Antibody distribution of the patient group. The PRA testing was currently performed and levels above 30% were accepted to be positive. The PRA class I positivity was determined in 24 (7%) and class II in 34 (10%) of the patients. The most frequent HLA antibodies for class I were B56, A2, A34, A1, A23, A24 and B61; and for class II were DR11, DR14, DQ7, DR10, DQ5, DR1 and DR7, respectively. From these, the increase of the numbers of anti-HLA class II antibodies was significantly correlated with the increase of PRA sensitization ratio. In conclusion, the identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA antigen distribution will identify the high-risk patients who are candidates for transplantation.
-
angiotensin converting enzyme genotype is a predictive factor in the peak Panel Reactive Antibody response
Transplantation proceedings, 2004Co-Authors: Ali Akcay, Siren Sezer, Fatma Belgin Atac, Hasibe Verdi, F N Ozdemir, Z Arat, Mehmet HaberalAbstract:The presence of a high Panel-Reactive Antibody (PRA) level represents an independent risk factor for early graft failure and chronic allograft dysfunction. It has also been reported that patients with the ACE-DD and AGT-AA genotypes display poorer chronic allograft function. We investigated the effects of gene polymorphisms of the renin angiotensin system (RAS) on anti-HLA Antibody production among renal transplant candidates. Genotyping was performed on 133 dialysis patients for the ACE (I/D) and AGT (M235T) as well as the type 1 (A1166C) and type 2 (A1223G) angiotensin II receptor genes. Patients with a peak PRA ≥ 30% were considered to be positive for anti-HLA Antibody (40.6% of 133 patients). Genetic polymorphisms of the RAS were not associated with anti-HLA Antibody production at this PRA level. Another analysis comparing the 29 patients with a peak PRA ≥50% with the 104 patients with a peak PRA <50% showed that previous transplants, the presence of ACE-DD genotype, history of blood transfusions, and dialysis duration were all associated with the high levels of Antibody production by univariant analysis. A multivariate analysis using a logistic regression model revealed previous transplants, the presence of ACE-DD genotype, and history of blood transfusions to be predictors of anti-HLA Antibody production. The ACE-DD genotype is an important risk factor for higher PRA levels. This study suggests that genetic control of RAS activity correlates with production of anti-HLA antibodies, possibly explaining the relationship to chronic allograft outcome.
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish end stage renal disease patients
Tissue Antigens, 2002Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, A Gulmus, E Kulah, Mehmet HaberalAbstract:Pre and postrenal transplantation Panel Reactive Antibody (PRA) screening is associated with increased rates of hyperacute or acute-graft rejection and graft loss. It has been suggested that phenotypic HLA-antigens are involved in PRA sensitization. This study investigated the relationships between HLA-specific Antibody frequencies and PRA sensitization in Turkish patients with end-stage renal disease (ESRD). Three hundred and forty patients on the renal transplantation waiting list participated. We determined the level of PRA sensitization and the candidates' class I and II HLA-Antibody profile. Panel Reactive Antibody levels greater than 30% were accepted as positive. The frequencies of the different antibodies in the sensitized group were calculated. Twenty-four (7%) of the 340 patients showed PRA-ABC positivity and 34 (10%) showed DR positivity. Thirty-nine (11.5%) of the candidates were PRA-positive. The most frequent class I HLA-antibodies in this group were A2, A34, and B56, and the most frequent class II antibodies were DR1, DR7, DR10, DR11, DR14, DR52, DQ1, DQ4, DQ6, and DQ7. Analysis showed that the presence of each of these HLA class II antibodies was significantly correlated with PRA positivity. Apart from the presence of HLA-A2, A24, and DR11 antibodies, the HLA profile for the PRA-positive candidates differed from that of the general Turkish population. In conclusion, identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA-antigen distribution will identify high-risk patients as candidates for transplantation.
J Kobashigawa - One of the best experts on this subject based on the ideXlab platform.
-
sex differences in preformed Panel Reactive Antibody levels and outcomes in patients undergoing heart transplantation
Clinical Transplantation, 2019Co-Authors: Christina Magnussen, N Ruebsamen, Francisco Ojeda, Meike Rybczynski, Hermann Reichenspurner, Alexander M. Bernhardt, J Kobashigawa, Renate B. SchnabelAbstract:BACKGROUND Sex differences in Panel-Reactive Antibody (PRA) levels in heart transplant recipients and their association with transplant-related outcomes are mostly unknown. METHODS In 20 181 (24.7% women) first-time heart transplant recipients included from July 2004 to March 2015 in the prospective Organ Procurement and Transplantation Network (OPTN), we studied sex differences in most recent (mr) and peak (p)PRA and outcomes (graft failure, rejection, cardiac allograft vasculopathy [CAV], retransplantation, and mortality). Median follow-up (all-cause mortality) was 6 years. Analyses are based on OPTN data (March 6, 2017). RESULTS MrPRA levels were associated with all-cause mortality (hazard ratio, 95% confidence interval: class I 1.03, 1.01-1.04, P < 0.001) and acute rejection (class II 1.08, 1.03-1.14, P = 0.0044). PPRA levels were associated with all-cause mortality (class I 1.02, 1.00-1.04, P = 0.015) and CAV (class II 1.03, 1.01-1.06, P = 0.020). Sex interactions were seen for the association of pPRA and graft failure with a higher risk in women, and for pPRA and CAV with a higher risk in men. CONCLUSIONS PRA were associated with different transplant-related outcomes in both sexes. However, women with elevated pPRA were shown to be at higher risk for graft failure, whereas higher levels of pPRA were more hazardous for men in developing CAV.
-
calculated Panel Reactive Antibody predicts outcomes on the heart transplant waiting list
Journal of Heart and Lung Transplantation, 2017Co-Authors: E Kransdorf, M Kittleson, J Patel, Marcelo J Pando, Eric D Steidley, J KobashigawaAbstract:Background Sensitized heart transplant candidates spend more time and have higher mortality on the waiting list. Although the calculated Panel-Reactive Antibody (CPRA) value is used to assign allocation priority to kidney transplant candidates in the United States, the relationship between CPRA and outcomes on the heart transplant waiting list is unknown. Methods A data set of patients listed for heart transplant with unacceptable human leukocyte antigens (HLA) entered was obtained from the United Network for Organ Sharing. The study cohort was composed of 3,855 adult candidates listed for heart transplant between 2006 and 2013 with active waiting time. The cohort was divided into 5 groups by increasing CPRA. Outcomes were assessed using competing risks and sub-hazard regression analyses. Results In each group of successively higher CPRA, the percentage of candidates who received a transplant decreased, whereas the percentage of those who were still waiting for a transplant increased, as did the percentage of those removed from the waiting list or had died. The group of candidates with a CPRA >80% displayed a markedly decreased incidence of transplantation (hazard ratio 0.37) and an increased risk of removal from the waiting list or death (hazard ratio 2.18) as compared to those with CPRA of ≤10%. Conclusions Sensitized heart transplant candidates are at high risk of adverse outcomes on the heart transplant waiting list. Clinicians should strive to minimize the CPRA by maximizing specificity in the selection of HLA antigens to exclude. The optimal clinical approach for candidates with high CPRA requires further study.
-
the use of the calculated Panel Reactive Antibody and virtual crossmatch in heart transplantation
Current Opinion in Organ Transplantation, 2012Co-Authors: D H Chang, J KobashigawaAbstract:Purpose of reviewAlloantibodies to human leukocyte antigens (HLAs) in patients awaiting heart transplantation are associated with prolonged wait time to transplant, increased risk of posttransplant rejection and cardiac allograft vasculopathy, and decreased survival. Solid-phase assays to determine
-
pretransplant Panel Reactive Antibody screens are they truly a marker for poor outcome after cardiac transplantation
Circulation, 1996Co-Authors: J Kobashigawa, J Moriguchi, A Hage, Alejandro Sabad, G. A. Cogert, N. Kawata, M. A. Hamilton, Paul I. Terasaki, D C Drinkwater, Hillel LaksAbstract:Background The effect of pretransplant sensitization on outcome after cardiac transplant has been controversial. Sensitization, defined as a positive Panel-Reactive Antibody (PRA) screen in patients awaiting transplant, represents circulating antibodies to a random Panel of donor lymphocytes (usually T lymphocytes). The significance of pretransplant circulating antibodies to B lymphocytes has not been reported, and many centers disregard its use. Methods and Results We retrospectively reviewed the pretransplant PRA screens for 311 patients who underwent cardiac transplant at our institution. The PRA screen was performed by use of the lymphocytotoxic technique treated with dithiothreitol to remove IgM autoantibodies. Patients with PRA ≥11% against T or B lymphocytes had significantly lower 3-year survival (T lymphocytes, 39% ; B lymphocytes, 56%) than those patients with PRA=0% and PRA=1 % to 10% (T lymphocytes, 76% and 78% ; B lymphocytes, 78% and 74%, respectively) (P<.001). For this high-risk group, the rejection episode tended to occur earlier than in those patients with PRA=0% and PRA= 1 % to 10% (T lymphocytes, 2.3 versus 4.0 and 3.8 months ; B lymphocytes, 2.1 versus 4.1 and 3.4 months, respectively), and there were more clinically severe rejections that required OKT3 therapy. Conclusions Cardiac transplant patients with pretransplant T- and/or B-lymphocyte PRA ≥11% despite negative donor-specific crossmatch at the time of transplant appear to have earlier and more severe rejection with significantly lower survival after transplant surgery. Modification of immunosuppression in these high-risk patients may be warranted.
Siren Sezer - One of the best experts on this subject based on the ideXlab platform.
-
Angiotensin-converting enzyme genotype is a predictive factor in the peak Panel-Reactive Antibody response.
Transplantation proceedings, 2004Co-Authors: Ali Akcay, F N Ozdemir, Siren Sezer, Z Arat, Fatma Belgin Atac, Hasibe Verdi, Mehmet HaberalAbstract:The presence of a high Panel-Reactive Antibody (PRA) level represents an independent risk factor for early graft failure and chronic allograft dysfunction. It has also been reported that patients with the ACE-DD and AGT-AA genotypes display poorer chronic allograft function. We investigated the effects of gene polymorphisms of the renin angiotensin system (RAS) on anti-HLA Antibody production among renal transplant candidates. Genotyping was performed on 133 dialysis patients for the ACE (I/D) and AGT (M235T) as well as the type 1 (A1166C) and type 2 (A1223G) angiotensin II receptor genes. Patients with a peak PRA ≥ 30% were considered to be positive for anti-HLA Antibody (40.6% of 133 patients). Genetic polymorphisms of the RAS were not associated with anti-HLA Antibody production at this PRA level. Another analysis comparing the 29 patients with a peak PRA ≥50% with the 104 patients with a peak PRA
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish renal transplant candidates
Transplant Immunology, 2004Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, E Kulah, Ali Akcay, S Gulmus, Mehmet HaberalAbstract:Abstract Pre- and post-renal transplantation Panel Reactive Antibody (PRA) screening is associated with increased incidence of hyperacute or acute graft rejection and graft loss. This study was designed to find any relationship PRA sensitization and associated human leukocyte antigen (HLA)-specific antibodies in Turkish renal transplant candidates. We included 340 patients who were in the renal transplantation waiting list in the study. We determined PRA sensitization ratio and the associated anti-HLA IgG Antibody distribution of the patient group. The PRA testing was currently performed and levels above 30% were accepted to be positive. The PRA class I positivity was determined in 24 (7%) and class II in 34 (10%) of the patients. The most frequent HLA antibodies for class I were B56, A2, A34, A1, A23, A24 and B61; and for class II were DR11, DR14, DQ7, DR10, DQ5, DR1 and DR7, respectively. From these, the increase of the numbers of anti-HLA class II antibodies was significantly correlated with the increase of PRA sensitization ratio. In conclusion, the identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA antigen distribution will identify the high-risk patients who are candidates for transplantation.
-
angiotensin converting enzyme genotype is a predictive factor in the peak Panel Reactive Antibody response
Transplantation proceedings, 2004Co-Authors: Ali Akcay, Siren Sezer, Fatma Belgin Atac, Hasibe Verdi, F N Ozdemir, Z Arat, Mehmet HaberalAbstract:The presence of a high Panel-Reactive Antibody (PRA) level represents an independent risk factor for early graft failure and chronic allograft dysfunction. It has also been reported that patients with the ACE-DD and AGT-AA genotypes display poorer chronic allograft function. We investigated the effects of gene polymorphisms of the renin angiotensin system (RAS) on anti-HLA Antibody production among renal transplant candidates. Genotyping was performed on 133 dialysis patients for the ACE (I/D) and AGT (M235T) as well as the type 1 (A1166C) and type 2 (A1223G) angiotensin II receptor genes. Patients with a peak PRA ≥ 30% were considered to be positive for anti-HLA Antibody (40.6% of 133 patients). Genetic polymorphisms of the RAS were not associated with anti-HLA Antibody production at this PRA level. Another analysis comparing the 29 patients with a peak PRA ≥50% with the 104 patients with a peak PRA <50% showed that previous transplants, the presence of ACE-DD genotype, history of blood transfusions, and dialysis duration were all associated with the high levels of Antibody production by univariant analysis. A multivariate analysis using a logistic regression model revealed previous transplants, the presence of ACE-DD genotype, and history of blood transfusions to be predictors of anti-HLA Antibody production. The ACE-DD genotype is an important risk factor for higher PRA levels. This study suggests that genetic control of RAS activity correlates with production of anti-HLA antibodies, possibly explaining the relationship to chronic allograft outcome.
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish end stage renal disease patients
Tissue Antigens, 2002Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, A Gulmus, E Kulah, Mehmet HaberalAbstract:Pre and postrenal transplantation Panel Reactive Antibody (PRA) screening is associated with increased rates of hyperacute or acute-graft rejection and graft loss. It has been suggested that phenotypic HLA-antigens are involved in PRA sensitization. This study investigated the relationships between HLA-specific Antibody frequencies and PRA sensitization in Turkish patients with end-stage renal disease (ESRD). Three hundred and forty patients on the renal transplantation waiting list participated. We determined the level of PRA sensitization and the candidates' class I and II HLA-Antibody profile. Panel Reactive Antibody levels greater than 30% were accepted as positive. The frequencies of the different antibodies in the sensitized group were calculated. Twenty-four (7%) of the 340 patients showed PRA-ABC positivity and 34 (10%) showed DR positivity. Thirty-nine (11.5%) of the candidates were PRA-positive. The most frequent class I HLA-antibodies in this group were A2, A34, and B56, and the most frequent class II antibodies were DR1, DR7, DR10, DR11, DR14, DR52, DQ1, DQ4, DQ6, and DQ7. Analysis showed that the presence of each of these HLA class II antibodies was significantly correlated with PRA positivity. Apart from the presence of HLA-A2, A24, and DR11 antibodies, the HLA profile for the PRA-positive candidates differed from that of the general Turkish population. In conclusion, identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA-antigen distribution will identify high-risk patients as candidates for transplantation.
-
Panel‐Reactive Antibody POSITIVITY AND ASSOCIATED HLA‐ANTIBODIES IN TURKISH END‐STAGE RENAL DISEASE PATIENTS
Tissue Antigens, 2002Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, A Gulmus, E Kulah, Mehmet HaberalAbstract:Pre and postrenal transplantation Panel Reactive Antibody (PRA) screening is associated with increased rates of hyperacute or acute-graft rejection and graft loss. It has been suggested that phenotypic HLA-antigens are involved in PRA sensitization. This study investigated the relationships between HLA-specific Antibody frequencies and PRA sensitization in Turkish patients with end-stage renal disease (ESRD). Three hundred and forty patients on the renal transplantation waiting list participated. We determined the level of PRA sensitization and the candidates' class I and II HLA-Antibody profile. Panel Reactive Antibody levels greater than 30% were accepted as positive. The frequencies of the different antibodies in the sensitized group were calculated. Twenty-four (7%) of the 340 patients showed PRA-ABC positivity and 34 (10%) showed DR positivity. Thirty-nine (11.5%) of the candidates were PRA-positive. The most frequent class I HLA-antibodies in this group were A2, A34, and B56, and the most frequent class II antibodies were DR1, DR7, DR10, DR11, DR14, DR52, DQ1, DQ4, DQ6, and DQ7. Analysis showed that the presence of each of these HLA class II antibodies was significantly correlated with PRA positivity. Apart from the presence of HLA-A2, A24, and DR11 antibodies, the HLA profile for the PRA-positive candidates differed from that of the general Turkish population. In conclusion, identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA-antigen distribution will identify high-risk patients as candidates for transplantation.
F N Ozdemir - One of the best experts on this subject based on the ideXlab platform.
-
Angiotensin-converting enzyme genotype is a predictive factor in the peak Panel-Reactive Antibody response.
Transplantation proceedings, 2004Co-Authors: Ali Akcay, F N Ozdemir, Siren Sezer, Z Arat, Fatma Belgin Atac, Hasibe Verdi, Mehmet HaberalAbstract:The presence of a high Panel-Reactive Antibody (PRA) level represents an independent risk factor for early graft failure and chronic allograft dysfunction. It has also been reported that patients with the ACE-DD and AGT-AA genotypes display poorer chronic allograft function. We investigated the effects of gene polymorphisms of the renin angiotensin system (RAS) on anti-HLA Antibody production among renal transplant candidates. Genotyping was performed on 133 dialysis patients for the ACE (I/D) and AGT (M235T) as well as the type 1 (A1166C) and type 2 (A1223G) angiotensin II receptor genes. Patients with a peak PRA ≥ 30% were considered to be positive for anti-HLA Antibody (40.6% of 133 patients). Genetic polymorphisms of the RAS were not associated with anti-HLA Antibody production at this PRA level. Another analysis comparing the 29 patients with a peak PRA ≥50% with the 104 patients with a peak PRA
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish renal transplant candidates
Transplant Immunology, 2004Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, E Kulah, Ali Akcay, S Gulmus, Mehmet HaberalAbstract:Abstract Pre- and post-renal transplantation Panel Reactive Antibody (PRA) screening is associated with increased incidence of hyperacute or acute graft rejection and graft loss. This study was designed to find any relationship PRA sensitization and associated human leukocyte antigen (HLA)-specific antibodies in Turkish renal transplant candidates. We included 340 patients who were in the renal transplantation waiting list in the study. We determined PRA sensitization ratio and the associated anti-HLA IgG Antibody distribution of the patient group. The PRA testing was currently performed and levels above 30% were accepted to be positive. The PRA class I positivity was determined in 24 (7%) and class II in 34 (10%) of the patients. The most frequent HLA antibodies for class I were B56, A2, A34, A1, A23, A24 and B61; and for class II were DR11, DR14, DQ7, DR10, DQ5, DR1 and DR7, respectively. From these, the increase of the numbers of anti-HLA class II antibodies was significantly correlated with the increase of PRA sensitization ratio. In conclusion, the identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA antigen distribution will identify the high-risk patients who are candidates for transplantation.
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish end stage renal disease patients
Tissue Antigens, 2002Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, A Gulmus, E Kulah, Mehmet HaberalAbstract:Pre and postrenal transplantation Panel Reactive Antibody (PRA) screening is associated with increased rates of hyperacute or acute-graft rejection and graft loss. It has been suggested that phenotypic HLA-antigens are involved in PRA sensitization. This study investigated the relationships between HLA-specific Antibody frequencies and PRA sensitization in Turkish patients with end-stage renal disease (ESRD). Three hundred and forty patients on the renal transplantation waiting list participated. We determined the level of PRA sensitization and the candidates' class I and II HLA-Antibody profile. Panel Reactive Antibody levels greater than 30% were accepted as positive. The frequencies of the different antibodies in the sensitized group were calculated. Twenty-four (7%) of the 340 patients showed PRA-ABC positivity and 34 (10%) showed DR positivity. Thirty-nine (11.5%) of the candidates were PRA-positive. The most frequent class I HLA-antibodies in this group were A2, A34, and B56, and the most frequent class II antibodies were DR1, DR7, DR10, DR11, DR14, DR52, DQ1, DQ4, DQ6, and DQ7. Analysis showed that the presence of each of these HLA class II antibodies was significantly correlated with PRA positivity. Apart from the presence of HLA-A2, A24, and DR11 antibodies, the HLA profile for the PRA-positive candidates differed from that of the general Turkish population. In conclusion, identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA-antigen distribution will identify high-risk patients as candidates for transplantation.
-
Panel‐Reactive Antibody POSITIVITY AND ASSOCIATED HLA‐ANTIBODIES IN TURKISH END‐STAGE RENAL DISEASE PATIENTS
Tissue Antigens, 2002Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, A Gulmus, E Kulah, Mehmet HaberalAbstract:Pre and postrenal transplantation Panel Reactive Antibody (PRA) screening is associated with increased rates of hyperacute or acute-graft rejection and graft loss. It has been suggested that phenotypic HLA-antigens are involved in PRA sensitization. This study investigated the relationships between HLA-specific Antibody frequencies and PRA sensitization in Turkish patients with end-stage renal disease (ESRD). Three hundred and forty patients on the renal transplantation waiting list participated. We determined the level of PRA sensitization and the candidates' class I and II HLA-Antibody profile. Panel Reactive Antibody levels greater than 30% were accepted as positive. The frequencies of the different antibodies in the sensitized group were calculated. Twenty-four (7%) of the 340 patients showed PRA-ABC positivity and 34 (10%) showed DR positivity. Thirty-nine (11.5%) of the candidates were PRA-positive. The most frequent class I HLA-antibodies in this group were A2, A34, and B56, and the most frequent class II antibodies were DR1, DR7, DR10, DR11, DR14, DR52, DQ1, DQ4, DQ6, and DQ7. Analysis showed that the presence of each of these HLA class II antibodies was significantly correlated with PRA positivity. Apart from the presence of HLA-A2, A24, and DR11 antibodies, the HLA profile for the PRA-positive candidates differed from that of the general Turkish population. In conclusion, identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA-antigen distribution will identify high-risk patients as candidates for transplantation.
Z Arat - One of the best experts on this subject based on the ideXlab platform.
-
Angiotensin-converting enzyme genotype is a predictive factor in the peak Panel-Reactive Antibody response.
Transplantation proceedings, 2004Co-Authors: Ali Akcay, F N Ozdemir, Siren Sezer, Z Arat, Fatma Belgin Atac, Hasibe Verdi, Mehmet HaberalAbstract:The presence of a high Panel-Reactive Antibody (PRA) level represents an independent risk factor for early graft failure and chronic allograft dysfunction. It has also been reported that patients with the ACE-DD and AGT-AA genotypes display poorer chronic allograft function. We investigated the effects of gene polymorphisms of the renin angiotensin system (RAS) on anti-HLA Antibody production among renal transplant candidates. Genotyping was performed on 133 dialysis patients for the ACE (I/D) and AGT (M235T) as well as the type 1 (A1166C) and type 2 (A1223G) angiotensin II receptor genes. Patients with a peak PRA ≥ 30% were considered to be positive for anti-HLA Antibody (40.6% of 133 patients). Genetic polymorphisms of the RAS were not associated with anti-HLA Antibody production at this PRA level. Another analysis comparing the 29 patients with a peak PRA ≥50% with the 104 patients with a peak PRA
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish renal transplant candidates
Transplant Immunology, 2004Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, E Kulah, Ali Akcay, S Gulmus, Mehmet HaberalAbstract:Abstract Pre- and post-renal transplantation Panel Reactive Antibody (PRA) screening is associated with increased incidence of hyperacute or acute graft rejection and graft loss. This study was designed to find any relationship PRA sensitization and associated human leukocyte antigen (HLA)-specific antibodies in Turkish renal transplant candidates. We included 340 patients who were in the renal transplantation waiting list in the study. We determined PRA sensitization ratio and the associated anti-HLA IgG Antibody distribution of the patient group. The PRA testing was currently performed and levels above 30% were accepted to be positive. The PRA class I positivity was determined in 24 (7%) and class II in 34 (10%) of the patients. The most frequent HLA antibodies for class I were B56, A2, A34, A1, A23, A24 and B61; and for class II were DR11, DR14, DQ7, DR10, DQ5, DR1 and DR7, respectively. From these, the increase of the numbers of anti-HLA class II antibodies was significantly correlated with the increase of PRA sensitization ratio. In conclusion, the identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA antigen distribution will identify the high-risk patients who are candidates for transplantation.
-
Panel Reactive Antibody positivity and associated hla antibodies in turkish end stage renal disease patients
Tissue Antigens, 2002Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, A Gulmus, E Kulah, Mehmet HaberalAbstract:Pre and postrenal transplantation Panel Reactive Antibody (PRA) screening is associated with increased rates of hyperacute or acute-graft rejection and graft loss. It has been suggested that phenotypic HLA-antigens are involved in PRA sensitization. This study investigated the relationships between HLA-specific Antibody frequencies and PRA sensitization in Turkish patients with end-stage renal disease (ESRD). Three hundred and forty patients on the renal transplantation waiting list participated. We determined the level of PRA sensitization and the candidates' class I and II HLA-Antibody profile. Panel Reactive Antibody levels greater than 30% were accepted as positive. The frequencies of the different antibodies in the sensitized group were calculated. Twenty-four (7%) of the 340 patients showed PRA-ABC positivity and 34 (10%) showed DR positivity. Thirty-nine (11.5%) of the candidates were PRA-positive. The most frequent class I HLA-antibodies in this group were A2, A34, and B56, and the most frequent class II antibodies were DR1, DR7, DR10, DR11, DR14, DR52, DQ1, DQ4, DQ6, and DQ7. Analysis showed that the presence of each of these HLA class II antibodies was significantly correlated with PRA positivity. Apart from the presence of HLA-A2, A24, and DR11 antibodies, the HLA profile for the PRA-positive candidates differed from that of the general Turkish population. In conclusion, identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA-antigen distribution will identify high-risk patients as candidates for transplantation.
-
Panel‐Reactive Antibody POSITIVITY AND ASSOCIATED HLA‐ANTIBODIES IN TURKISH END‐STAGE RENAL DISEASE PATIENTS
Tissue Antigens, 2002Co-Authors: F N Ozdemir, M Turan, Siren Sezer, Z Arat, A Gulmus, E Kulah, Mehmet HaberalAbstract:Pre and postrenal transplantation Panel Reactive Antibody (PRA) screening is associated with increased rates of hyperacute or acute-graft rejection and graft loss. It has been suggested that phenotypic HLA-antigens are involved in PRA sensitization. This study investigated the relationships between HLA-specific Antibody frequencies and PRA sensitization in Turkish patients with end-stage renal disease (ESRD). Three hundred and forty patients on the renal transplantation waiting list participated. We determined the level of PRA sensitization and the candidates' class I and II HLA-Antibody profile. Panel Reactive Antibody levels greater than 30% were accepted as positive. The frequencies of the different antibodies in the sensitized group were calculated. Twenty-four (7%) of the 340 patients showed PRA-ABC positivity and 34 (10%) showed DR positivity. Thirty-nine (11.5%) of the candidates were PRA-positive. The most frequent class I HLA-antibodies in this group were A2, A34, and B56, and the most frequent class II antibodies were DR1, DR7, DR10, DR11, DR14, DR52, DQ1, DQ4, DQ6, and DQ7. Analysis showed that the presence of each of these HLA class II antibodies was significantly correlated with PRA positivity. Apart from the presence of HLA-A2, A24, and DR11 antibodies, the HLA profile for the PRA-positive candidates differed from that of the general Turkish population. In conclusion, identification of the associated HLA-specific antibodies and correlation with the Turkish population HLA-antigen distribution will identify high-risk patients as candidates for transplantation.
